3,250 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Johnson Financial Group Inc.

Johnson Financial Group Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 3,250 shares of the biopharmaceutical company’s stock, valued at approximately $2,027,000.

A number of other institutional investors have also recently bought and sold shares of the business. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru as the first and only treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation in soft tissues. In the placebo-controlled OPTIMA trial, Pasatru reduced new heterotopic ossification lesions by at least 90% at 56 weeks and significantly reduced clinician-assessed flare-ups. The approval adds a potential commercial product and strengthens Regeneron’s rare-disease portfolio. Reuters FDA approval article
• Positive Sentiment: The Pasatru approval is supported by meaningful clinical efficacy in a condition with limited treatment options, potentially giving Regeneron pricing and market-entry advantages in a highly specialized market. The financial contribution may initially be limited by FOP’s very small patient population, but the regulatory milestone can improve long-term pipeline value. Pasatru approval announcement
• Neutral Sentiment: Regeneron announced upcoming investor conference presentations by management. The events could provide additional details on Pasatru’s launch, the broader pipeline and financial outlook, but the announcement itself does not change current earnings expectations. Regeneron investor conference announcement
• Positive Sentiment: Leerink Partners raised its price target for REGN to $824, signaling continued analyst support for the shares, although the target may not fully reflect the latest trading level. Leerink Partners price target article
• Negative Sentiment: Several law firms publicized securities class actions and a September 14, 2026 lead-plaintiff deadline concerning allegations that Regeneron misrepresented risks surrounding the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, creating litigation costs, reputational risk and uncertainty around the oncology pipeline. These notices largely repeat the same underlying allegations rather than represent new operational developments. Regeneron class action notice

Insider Activity

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $840.84 on Thursday. The company has a market capitalization of $86.57 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 1.38 and a beta of 0.22. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $844.92. The stock’s 50 day moving average is $688.35 and its 200-day moving average is $715.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the firm posted $12.81 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Ratings Changes

Several brokerages have recently commented on REGN. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Finally, Barclays dropped their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.